{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T17:37:52Z","timestamp":1775151472927,"version":"3.50.1"},"reference-count":42,"publisher":"American Academy of Pediatrics (AAP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,3,1]]},"abstract":"<jats:p>OBJECTIVE. We sought to provide long-term data on the clinical, immunologic, and virologic response to highly active antiretroviral therapy in infants and children who are naive to protease inhibitors.<\/jats:p>\n               <jats:p>METHODS. HIV-1\u2013infected children who were naive to protease inhibitors were treated with a combination of nelfinavir and 2 nucleoside reverse transcriptase inhibitors (stavudine and lamivudine) in an observational, prospective, single-center study. Virologic failure-free survival was assessed by Kaplan-Meier analyses. The increase in CD4+ T cells during follow-up was estimated with a generalized linear model incorporating repeated measurements.<\/jats:p>\n               <jats:p>RESULTS. Thirty-nine HIV-1\u2013infected children were included and followed for a median period of 227 weeks (interquartile range: 108\u2013275 weeks). The virologic failure-free survival rate was 74%, 66%, 58%, and 54% after 48, 96, 144, and 240 weeks, respectively. Children who experienced virologic failure in 48 weeks (or 96 weeks) were younger at baseline compared with the responders (0.8 vs 5.3 years). Eighteen children remained on the regimen for &amp;gt;5 years. All children, including the nonresponders, showed a sustained immunologic response. Grades 3 to 4 toxicity was observed in 2 patients only. Eleven developed clinically evident lipodystrophy.<\/jats:p>\n               <jats:p>CONCLUSION. Combination therapy can be used safely in infants and children over a long period. Young age is strongly associated with virologic failure. Although the virologic response declined, immunologic parameters and clinical improvement were sustained up to 7 years, at the expense of lipodystrophy.<\/jats:p>","DOI":"10.1542\/peds.2005-1272","type":"journal-article","created":{"date-parts":[[2006,2,16]],"date-time":"2006-02-16T01:43:26Z","timestamp":1140054206000},"page":"e528-e536","source":"Crossref","is-referenced-by-count":20,"title":["Long-term Experience With Combination Antiretroviral Therapy That Contains Nelfinavir for up to 7 Years in a Pediatric Cohort"],"prefix":"10.1542","volume":"117","author":[{"given":"Henrie\u0308tte J.","family":"Scherpbier","sequence":"first","affiliation":[{"name":"Emma Children's Hospital, Academic Medical Center, Amsterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Bekker","sequence":"additional","affiliation":[{"name":"Emma Children's Hospital, Academic Medical Center, Amsterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"van Leth","sequence":"additional","affiliation":[{"name":"International Antiviral Therapy Evaluation Center, Amsterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"Jurriaans","sequence":"additional","affiliation":[{"name":"Academic Medical Center, Department of Human Retrovirology, Amsterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joep M.A.","family":"Lange","sequence":"additional","affiliation":[{"name":"International Antiviral Therapy Evaluation Center, Amsterdam, Netherlands"},{"name":"Academic Medical Center, Department of Internal Medicine, Division of Infectious Diseases, Tropical Medicine and AIDS, Amsterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taco W.","family":"Kuijpers","sequence":"additional","affiliation":[{"name":"Emma Children's Hospital, Academic Medical Center, Amsterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2006,3,1]]},"reference":[{"key":"2021120820103500400_R1","doi-asserted-by":"crossref","unstructured":"Krogstad P, Wiznia A, Luzuriaga K, et al. Treatment of human immunodeficiency virus 1-infected children with the protease inhibitor nelfinavir mesylate. Clin Infect Dis.\u20081999;28:1109\u20131118","DOI":"10.1086\/514759"},{"key":"2021120820103500400_R2","doi-asserted-by":"crossref","unstructured":"Mueller BU, Nelson RP Jr, Sleasman J, et al. A phase I\/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection. Pediatrics.\u20081998;101:335\u2013343","DOI":"10.1542\/peds.101.3.335"},{"key":"2021120820103500400_R3","doi-asserted-by":"crossref","unstructured":"Kline MW, Fletcher CV, Harris AT, et al. A pilot study of combination therapy with indinavir, stavudine (d4T), didanosine (ddI) in children with the human immunodeficiency virus. J Pediatr.\u20081998;132:543\u2013546","DOI":"10.1016\/S0022-3476(98)70039-3"},{"key":"2021120820103500400_R4","doi-asserted-by":"crossref","unstructured":"Gibb DM, Duong T, Tookey PA, et al. Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland. BMJ.\u20082003;327:1019\u20131024","DOI":"10.1136\/bmj.327.7422.1019"},{"key":"2021120820103500400_R5","doi-asserted-by":"crossref","unstructured":"Viani RM, Araneta MRG, Deville JG, Spector SA. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy. Clin Infect Dis.\u20082004;39:725\u2013731","DOI":"10.1086\/423178"},{"key":"2021120820103500400_R6","doi-asserted-by":"crossref","unstructured":"Gortmaker SL, Hughes M, Cervia J, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med.\u20082001;345:1522\u20131528","DOI":"10.1056\/NEJMoa011157"},{"key":"2021120820103500400_R7","doi-asserted-by":"crossref","unstructured":"Kaufmann GR, Perrin L, Pantaleo G, et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med.\u20082003;163:2187\u20132195","DOI":"10.1001\/archinte.163.18.2187"},{"key":"2021120820103500400_R8","doi-asserted-by":"crossref","unstructured":"Hunt PW, Deeks SG, Rodriguez B, et al. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression during antiretroviral therapy. AIDS.\u20082003;17:1907\u20131915","DOI":"10.1097\/00002030-200309050-00009"},{"key":"2021120820103500400_R9","doi-asserted-by":"crossref","unstructured":"Soh C, Oleske JM, Brady MT, et al. Long-term effects of protease-inhibitor-based combination therapy on CD4 T-cell recovery in HIV-1-infected children and adolescents. Lancet.\u20082003;362:2045\u20132051","DOI":"10.1016\/S0140-6736(03)15098-2"},{"key":"2021120820103500400_R10","doi-asserted-by":"crossref","unstructured":"Funk MB, Linde R, Wintergeist U, et al. Preliminary experiences with triple therapy including nelfinavir and two reverse transcriptase inhibitors in previously untreated HIV-infected children. AIDS.\u20081999;13:1653\u20131658","DOI":"10.1097\/00002030-199909100-00008"},{"key":"2021120820103500400_R11","doi-asserted-by":"crossref","unstructured":"Starr SE, Fletcher CV, Spector SA, et al. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. N Engl J Med.\u20081999;341:1874\u20131881","DOI":"10.1056\/NEJM199912163412502"},{"key":"2021120820103500400_R12","doi-asserted-by":"crossref","unstructured":"Van Rossum AM, Geelen PM, Hartwig NG, et al. Results of 2 years of treatment with protease-inhibitor-containing antiretroviral therapy in Dutch children infected with human immunodeficiency virus type 1. Clin Infect Dis.\u20082002;34:1008\u20131016","DOI":"10.1086\/339443"},{"key":"2021120820103500400_R13","doi-asserted-by":"crossref","unstructured":"Walker AS, Doerholt K, Sharland M, Gibb DM. Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV Paediatric Study. AIDS.\u20082004;18:1915\u20131924","DOI":"10.1097\/00002030-200409240-00007"},{"key":"2021120820103500400_R14","doi-asserted-by":"crossref","unstructured":"van Rossum AM, Scherpbier HJ, van Lochem EG, et al. Therapeutic immune reconstitution in HIV-infected children is independent of their age and pretreatment immune status. AIDS.\u20082001;15:2267\u20132275","DOI":"10.1097\/00002030-200111230-00008"},{"key":"2021120820103500400_R15","unstructured":"Guidelines for the use of antiretroviral agents in pediatric HIV infection. Available at: aidsinfo.nih.gov. Accessed November 3, 2005"},{"key":"2021120820103500400_R16","doi-asserted-by":"crossref","unstructured":"Sharland M, di Zub GC, Ramos JT, Blanche S, Gibb DM. PENTA guidelines for the use of antiretroviral therapy in paediatric HIV infection. HIV Med.\u20082002;3:215\u2013226","DOI":"10.1046\/j.1468-1293.2002.00120.x"},{"key":"2021120820103500400_R17","doi-asserted-by":"crossref","unstructured":"Van Heeswijk RP, Scherpbier HJ, de Koning LA, et al. The pharmacokinetics of nelfinavir in HIV-1 infected children. Ther Drug Monit.\u20082002;24:487\u2013491","DOI":"10.1097\/00007691-200208000-00004"},{"key":"2021120820103500400_R18","doi-asserted-by":"crossref","unstructured":"Kuijpers TW, Vossen MT, Gent MR, et al. Frequencies of circulating cytolytic, CD45RA+CD27-, CD8+ T lymphocytes depend on infection with CMV. J Immunol.\u20082003;170:4342\u20134348","DOI":"10.4049\/jimmunol.170.8.4342"},{"key":"2021120820103500400_R19","doi-asserted-by":"crossref","unstructured":"Resino S, Bello\u0301n JM, Resino R, et al. Extensive implementation of highly active antiretroviral therapy shows great effect on survival and surrogate markers in vertically HIV-1 infected children. Clin Infect Dis.\u20082004;38:1605\u20131612","DOI":"10.1086\/420738"},{"key":"2021120820103500400_R20","doi-asserted-by":"crossref","unstructured":"Luzuriaga K, McManus M, Mofenson L, Britto P, Graham BS, Sullivan JL. A trial of three antiretroviral regimens in HIV-1 infected children. N Engl J Med.\u20082004;24:2471\u20132479","DOI":"10.1056\/NEJMoa032706"},{"key":"2021120820103500400_R21","doi-asserted-by":"crossref","unstructured":"Flynn PM, Rudy BJ, Douglas SD, et al. Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapy. J Infect Dis.\u20082004;190:271\u2013279","DOI":"10.1086\/421521"},{"key":"2021120820103500400_R22","doi-asserted-by":"crossref","unstructured":"Fraaij PLA, Verweel G, van Rossum AMC, et al. Sustained viral suppression and immune recovery in HIV type 1-infected children after 4 years of highly active antiretroviral therapy. Clin Infect Dis.\u20082005;40:604\u2013608","DOI":"10.1086\/427696"},{"key":"2021120820103500400_R23","doi-asserted-by":"crossref","unstructured":"Schuster T, Linde R, Wintergeist U, et al. Nelfinavir pharmacokinetics in HIV-infected children: a comparison of twice daily and three times daily. AIDS.\u20082000;14:1466\u20131468","DOI":"10.1097\/00002030-200007070-00029"},{"key":"2021120820103500400_R24","doi-asserted-by":"crossref","unstructured":"Litalien C, Faye A, Compagnucci A, et al. Pharmacokinetics of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1. Pediatr Infect Dis J.\u20082003;22:48\u201355","DOI":"10.1097\/00006454-200301000-00014"},{"key":"2021120820103500400_R25","unstructured":"van Leth F, Kappelhoff BS, Johnson D, et al. Pharmacokinetic parameters of nevirapine and efavirenz in relation to virologic failure. AIDS Research and Human Retroviruses. In press"},{"key":"2021120820103500400_R26","unstructured":"Bekker V, Sherpbier HJ, Steingrover R, Lange JMA, Wolthers K, Kuijpers TW. Viral dynamics after starting HAART in HIV-1 infected children are not correlated with age. AIDS Research and Human Retroviruses. In press"},{"key":"2021120820103500400_R27","doi-asserted-by":"crossref","unstructured":"Garcia F, de Lazzari E, Plana M, et al. Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count. J Acquir Immune Defic Syndr.\u20082004;36:702\u2013713","DOI":"10.1097\/00126334-200406010-00007"},{"key":"2021120820103500400_R28","doi-asserted-by":"crossref","unstructured":"Resino S, Gala\u0301n I, Pe\u0301rez A, et al. HIV-infected children with moderate\/severe immune-suppression: changes in the immune system after highly active antiretroviral therapy. Clin Exp Immunol.\u20082004;137:570\u2013577","DOI":"10.1111\/j.1365-2249.2004.02583.x"},{"key":"2021120820103500400_R29","doi-asserted-by":"crossref","unstructured":"De Rossi A, Walker AS, Klein N, De Forni D, King D, Gibb DM. Increased thymic output after initiation of antiretroviral therapy in human immunodeficiency virus type 1-infected children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 Trial. J Infect Dis.\u20082002;186:312\u2013320","DOI":"10.1086\/341657"},{"key":"2021120820103500400_R30","doi-asserted-by":"crossref","unstructured":"Chantry CJ, Byrd RS, Englund JA, Baker CJ, McKinney RS. Growth, survival and viral load in symptomatic childhood human immunodeficiency virus infection. Pediatr Infect Dis J.\u20082003;22:1033\u20131038","DOI":"10.1097\/01.inf.0000100575.64298.bc"},{"key":"2021120820103500400_R31","doi-asserted-by":"crossref","unstructured":"Sanchez Torres AM, Munoz Muniz R, Madero R, Borque C, Garcia-Miguel MJ, De Jose Gomez MI. Prevalence of fat redistribution and metabolic disorders in human immunodeficiency virus-infected children. Eur J Pediatr.\u20082005;164:271\u2013276","DOI":"10.1007\/s00431-004-1610-y"},{"key":"2021120820103500400_R32","doi-asserted-by":"crossref","unstructured":"de Martino M, Chiarelli F, Moriondo M, Torello M, Azzari C, Galli L. Restored antioxidant capacity parallels the immunologic and virologic improvement in children with perinatal human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Immunol.\u20082001;100:82\u201386","DOI":"10.1006\/clim.2001.5042"},{"key":"2021120820103500400_R33","doi-asserted-by":"crossref","unstructured":"Hardin DS, Ellis KJ, Rice J, Doyle ME. Protease inhibitor therapy improves protein catabolism in prepubertal children with HIV infection. J Pediatr Endocrinol Metab.\u20082004;17:321\u2013325","DOI":"10.1515\/JPEM.2004.17.3.321"},{"key":"2021120820103500400_R34","doi-asserted-by":"crossref","unstructured":"De Martin M, Tovo PA, Galli L, et al. Puberty in perinatal HIV-1 infection: a multicentre longitudinal study of 212 children. AIDS.\u20082001;15:1527\u20131534","DOI":"10.1097\/00002030-200108170-00010"},{"key":"2021120820103500400_R35","doi-asserted-by":"crossref","unstructured":"Vigano A, Mora S, Brambilla P, Schneider L, et al. Impaired growth hormone secretion correlates with visceral adiposity in highly active antiretroviral treated HIV-infected adolescents. AIDS.\u20082003;17:1435\u20131441","DOI":"10.1097\/00002030-200307040-00003"},{"key":"2021120820103500400_R36","doi-asserted-by":"crossref","unstructured":"Van Rossum AM, Gaakeer MI, Verweel S, et al. Endocrinologic and immunologic factors associated with recovery of growth in children with human immunodeficiency virus type 1 infection treated with protease inhibitors. Pediatr Infect Dis J.\u20082003;22:70\u201376","DOI":"10.1097\/00006454-200301000-00017"},{"key":"2021120820103500400_R37","doi-asserted-by":"crossref","unstructured":"European Paediatric Lipodystrophy Group. Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe. AIDS.\u20082004;18:1443\u20131451","DOI":"10.1097\/01.aids.0000131334.38172.01"},{"key":"2021120820103500400_R38","doi-asserted-by":"crossref","unstructured":"Dreimane D, Nielsen K, Deveikes A, Gegrz RC. Effects of protease inhibitors combine with standard antiretroviral therapy on linear growth and weight gain in immunodeficiency virus type 1-infected children. Pediatr Infect Dis J.\u20082001;20:315\u2013316","DOI":"10.1097\/00006454-200103000-00020"},{"key":"2021120820103500400_R39","doi-asserted-by":"crossref","unstructured":"Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth. Pediatrics.\u20082002;109(2). Available at: www.pediatrics.org\/cgi\/content\/full\/109\/2\/e25","DOI":"10.1542\/peds.109.2.e25"},{"key":"2021120820103500400_R40","doi-asserted-by":"crossref","unstructured":"Steiner F, Kind C, Aebi C, et al. Growth in human immunodeficiency virus type 1-infected children treated with protease inhibitors. Eur J Paediatr.\u20082001;160:611\u2013616","DOI":"10.1007\/s004310100820"},{"key":"2021120820103500400_R41","doi-asserted-by":"crossref","unstructured":"Brogley S, Williams P, Sage GR, et al, for the PCTG 219C. Antiretroviral treatment I pediatric HIV infection in the United States. JAMA.\u20082005;293:2213\u20132220","DOI":"10.1001\/jama.293.18.2213"},{"key":"2021120820103500400_R42","doi-asserted-by":"crossref","unstructured":"Yogev R. Balancing the upside and downside of antiretroviral therapy in children. JAMA.\u20082005;293:2272\u20132274","DOI":"10.1001\/jama.293.18.2272"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/117\/3\/e528\/1069961\/zpe0030600e528.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/117\/3\/e528\/1069961\/zpe0030600e528.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T23:44:40Z","timestamp":1639007080000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/117\/3\/e528\/68561\/Long-term-Experience-With-Combination"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3,1]]},"references-count":42,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2006,3,1]]},"published-print":{"date-parts":[[2006,3,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2005-1272","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,3,1]]}}}